Chronic Myeloid Leukaemia

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Chronic Myeloid Leukaemia is a tri-phasic myeloproliferative disorder. Patients usually present in chronic phase, characterised by granulocytosis and thrombocytosis. Splenomegaly is common. Without effective treatment, the disease progresses to an accelerated phase characterised by increasing white cell count, clonal evolution and rising blast count, culminating in a terminal blastic phase morphologically indistinguishable from acute leukaemia. Formation of the BCR-ABL1 fusion oncogene through translocation of chromosomes 9 and 22 is the underlying genetic lesion, encoding a constitutively active tyrosine kinase. This leads to growth disinhibition, and reduced apoptosis. Treatment with tyrosine kinase inhibitors (TKI) is highly effective in chronic phase and leads to excellent long term survival, though treatment responses in blastic phase disease with TKI monotherapy is usually transient.

Original languageEnglish
Title of host publicationPostgraduate Haematology
Subtitle of host publicationSeventh Edition
PublisherWiley Blackwell
Number of pages19
ISBN (Electronic)9781118853771
ISBN (Print)9781118854327
Publication statusPublished or Issued - 6 Nov 2015
Externally publishedYes


  • Atypical CML
  • Chronic myeloid leukaemia
  • Chronic neutrophilic leukaemia
  • Dasatinib
  • Imatinib
  • Kinase domain mutations
  • Nilotinib
  • Philadelphia Chromosome
  • Treatment Free Remission

ASJC Scopus subject areas

  • Medicine(all)

Cite this